vs
EXACT SCIENCES CORP（EXAS）与Fidelity National Financial, Inc.（FNF）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是Fidelity National Financial, Inc.的1.6倍（$878.4M vs $544.0M），EXACT SCIENCES CORP净利率更高（-9.8% vs -21.5%，领先11.7%），EXACT SCIENCES CORP同比增速更快（23.1% vs 10.3%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 13.7%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
富达国民金融是美国财富500强企业，主要面向房地产与抵押贷款行业提供产权保险及交割服务，2019年其产权及房地产业务相关年度营收约为84.69亿美元，是全球领先的产权保险服务供应商。
EXAS vs FNF — 直观对比
营收规模更大
EXAS
是对方的1.6倍
$544.0M
营收增速更快
EXAS
高出12.8%
10.3%
净利率更高
EXAS
高出11.7%
-21.5%
两年增速更快
EXAS
近两年复合增速
13.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $544.0M |
| 净利润 | $-86.0M | $-117.0M |
| 毛利率 | 70.1% | — |
| 营业利润率 | -9.4% | 82.9% |
| 净利率 | -9.8% | -21.5% |
| 营收同比 | 23.1% | 10.3% |
| 净利润同比 | 90.1% | -126.0% |
| 每股收益（稀释后） | $-0.45 | $-0.44 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASFNF
| Q4 25 | $878.4M | $544.0M | ||
| Q3 25 | $850.7M | $553.0M | ||
| Q2 25 | $811.1M | $547.0M | ||
| Q1 25 | $706.8M | $455.0M | ||
| Q4 24 | $713.4M | $493.0M | ||
| Q3 24 | $708.7M | $506.0M | ||
| Q2 24 | $699.3M | $504.0M | ||
| Q1 24 | $637.5M | $421.0M |
净利润EXASFNF
| Q4 25 | $-86.0M | $-117.0M | ||
| Q3 25 | $-19.6M | $358.0M | ||
| Q2 25 | $-1.2M | $278.0M | ||
| Q1 25 | $-101.2M | $83.0M | ||
| Q4 24 | $-864.6M | $450.0M | ||
| Q3 24 | $-38.2M | $266.0M | ||
| Q2 24 | $-15.8M | $306.0M | ||
| Q1 24 | $-110.2M | $248.0M |
毛利率EXASFNF
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — | ||
| Q1 24 | 70.0% | — |
营业利润率EXASFNF
| Q4 25 | -9.4% | 82.9% | ||
| Q3 25 | -3.0% | 81.9% | ||
| Q2 25 | -0.3% | 69.8% | ||
| Q1 25 | -13.6% | 24.4% | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | 61.9% | ||
| Q2 24 | -3.8% | 90.9% | ||
| Q1 24 | -16.7% | 78.6% |
净利率EXASFNF
| Q4 25 | -9.8% | -21.5% | ||
| Q3 25 | -2.3% | 64.7% | ||
| Q2 25 | -0.1% | 50.8% | ||
| Q1 25 | -14.3% | 18.2% | ||
| Q4 24 | -121.2% | 91.3% | ||
| Q3 24 | -5.4% | 52.6% | ||
| Q2 24 | -2.3% | 60.7% | ||
| Q1 24 | -17.3% | 58.9% |
每股收益（稀释后）EXASFNF
| Q4 25 | $-0.45 | $-0.44 | ||
| Q3 25 | $-0.10 | $1.33 | ||
| Q2 25 | $-0.01 | $1.02 | ||
| Q1 25 | $-0.54 | $0.30 | ||
| Q4 24 | $-4.69 | $1.65 | ||
| Q3 24 | $-0.21 | $0.97 | ||
| Q2 24 | $-0.09 | $1.12 | ||
| Q1 24 | $-0.60 | $0.91 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $2.6B |
| 总债务越低越好 | — | $4.4B |
| 股东权益账面价值 | $2.4B | $7.4B |
| 总资产 | $5.9B | $109.0B |
| 负债/权益比越低杠杆越低 | — | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资EXASFNF
| Q4 25 | $964.7M | $2.6B | ||
| Q3 25 | $1.0B | $3.5B | ||
| Q2 25 | $858.4M | $3.3B | ||
| Q1 25 | $786.2M | $4.5B | ||
| Q4 24 | $1.0B | $3.5B | ||
| Q3 24 | $1.0B | $5.0B | ||
| Q2 24 | $946.8M | $4.9B | ||
| Q1 24 | $652.1M | $3.5B |
总债务EXASFNF
| Q4 25 | — | $4.4B | ||
| Q3 25 | — | $4.4B | ||
| Q2 25 | — | $4.4B | ||
| Q1 25 | — | $4.4B | ||
| Q4 24 | — | $4.3B | ||
| Q3 24 | — | $4.2B | ||
| Q2 24 | — | $4.2B | ||
| Q1 24 | — | $3.9B |
股东权益EXASFNF
| Q4 25 | $2.4B | $7.4B | ||
| Q3 25 | $2.5B | $8.4B | ||
| Q2 25 | $2.5B | $7.9B | ||
| Q1 25 | $2.4B | $7.9B | ||
| Q4 24 | $2.4B | $7.8B | ||
| Q3 24 | $3.2B | $8.1B | ||
| Q2 24 | $3.2B | $7.3B | ||
| Q1 24 | $3.1B | $7.1B |
总资产EXASFNF
| Q4 25 | $5.9B | $109.0B | ||
| Q3 25 | $5.9B | $106.6B | ||
| Q2 25 | $5.8B | $102.3B | ||
| Q1 25 | $5.7B | $98.2B | ||
| Q4 24 | $5.9B | $95.4B | ||
| Q3 24 | $6.7B | $94.7B | ||
| Q2 24 | $6.7B | $88.8B | ||
| Q1 24 | $6.4B | $84.5B |
负债/权益比EXASFNF
| Q4 25 | — | 0.59× | ||
| Q3 25 | — | 0.53× | ||
| Q2 25 | — | 0.56× | ||
| Q1 25 | — | 0.56× | ||
| Q4 24 | — | 0.56× | ||
| Q3 24 | — | 0.52× | ||
| Q2 24 | — | 0.58× | ||
| Q1 24 | — | 0.55× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $1.5B |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASFNF
| Q4 25 | $151.7M | $1.5B | ||
| Q3 25 | $219.9M | $1.3B | ||
| Q2 25 | $89.0M | $1.9B | ||
| Q1 25 | $30.8M | $1.1B | ||
| Q4 24 | $47.1M | $1.5B | ||
| Q3 24 | $138.7M | $2.4B | ||
| Q2 24 | $107.1M | $1.4B | ||
| Q1 24 | $-82.3M | $1.6B |
自由现金流EXASFNF
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASFNF
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASFNF
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASFNF
| Q4 25 | — | — | ||
| Q3 25 | — | 3.66× | ||
| Q2 25 | — | 6.82× | ||
| Q1 25 | — | 13.43× | ||
| Q4 24 | — | 3.32× | ||
| Q3 24 | — | 8.89× | ||
| Q2 24 | — | 4.45× | ||
| Q1 24 | — | 6.42× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
FNF
| Escrow Fees | $241.0M | 44% |
| Other Title Related Fees And Income | $182.0M | 33% |
| Service Link Excluding Title Premiums Escrow Fees And Subservicing Fees | $87.0M | 16% |
| Insurance Contracts Home Warranty | $31.0M | 6% |
